TIGIT Protein (AA 22-141) (Fc Tag)

N° du produit ABIN4949144

Détail du produit

Antigène: TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT))

Type de proteíne: Recombinant

Activité biologique: Active

Attributs du protein: AA 22-141

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette TIGIT protéine est marqué à la Fc Tag.

Application: Functional Studies (Func)

Séquence: AA 22-141

Attributs du produit: This protein carries a mouse IgG2a Fc tag at the C-terminus. The protein has a calculated MW of 40.1 kDa. The protein migrates as 42-50 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.

Pureté: >95 % as determined by SDS-PAGE.

niveau d'endotoxine: Less than 0.1 EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Tris with Glycine, Arginine and NaCl,  pH 7.5

Conseil sur la manipulation: Please avoid repeated freeze-thaw cycles.

Stock: -20 °C

Détail du antigène

Antigène: TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT))

Autre désignation: TIGIT (TIGIT Produits)

Synonymes: VSIG9 Protein, VSTM3 Protein, WUCAM Protein, ENSMUSG00000071552 Protein, Vstm3 Protein, RGD1563191 Protein, T-cell immunoreceptor with Ig and ITIM domains Protein, T cell immunoreceptor with Ig and ITIM domains Protein, TIGIT Protein, Tigit Protein

Sujet: TIGIT (also called T cell immunoreceptor with Ig and ITIM domains) is one newly discovered immune receptor on some percentage of T cells and Natural Killer Cells(NK). It is also identified as WUCAM and Vstm3. TIGIT could bind to CD155(PVR) on dendritic cells(DCs), macrophages, etc. with high affinity, and also to CD112(PVRL2) with lower affinity. TIGIT expressing CD8+ T cells has been shown to be expanded and associated with clinical markers of HIV disease progression in a diverse group of HIV infected individuals. TIGIT and PD-1 has been shown to be over expressed on tumor antigen-sepcific (TA-specific) CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TILs) from individuals with melanoma. Blockade of TIGIT and PD-1 led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells.

Poids moléculaire: 40.1 kDa

Pathways: Cancer Immune Checkpoints